178 related articles for article (PubMed ID: 26106258)
1. Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease.
Guo Y; Zhou G; He C; Yang W; He Z; Liu Z
Mediators Inflamm; 2015; 2015():843089. PubMed ID: 26106258
[TBL] [Abstract][Full Text] [Related]
2. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
Feng T; Chen B; Li L; Huang S; Ben-Horin S; Qiu Y; Feng R; Li M; Mao R; He Y; Zeng Z; Zhang S; Chen M
Inflamm Bowel Dis; 2017 Oct; 23(10):1817-1824. PubMed ID: 28644181
[TBL] [Abstract][Full Text] [Related]
3. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa.
Yu L; Yang X; Xia L; Zhong J; Ge W; Wu J; Liu H; Liu F; Liu Z
Mediators Inflamm; 2015; 2015():793764. PubMed ID: 25873771
[TBL] [Abstract][Full Text] [Related]
4. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
5. Serum bacterial toxins are related to the progression of inflammatory bowel disease.
Qiu H; Sun X; Sun M; He C; Li Z; Liu Z
Scand J Gastroenterol; 2014 Jul; 49(7):826-33. PubMed ID: 24853095
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
Yamamoto K; Chiba T; Matsumoto T
World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
[TBL] [Abstract][Full Text] [Related]
7. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
8. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
[TBL] [Abstract][Full Text] [Related]
9. The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
Yu Q; Wang L; Zhang S; Feng T; Li L; Chen B; Chen M
Blood Transfus; 2016 Sep; 14(5):460-4. PubMed ID: 27136434
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn's disease.
Sun CM; Wu J; Zhang H; Shi G; Chen ZT
World J Gastroenterol; 2017 Nov; 23(44):7888-7898. PubMed ID: 29209130
[TBL] [Abstract][Full Text] [Related]
11. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
12. Serial changes of cytokines in Crohn's disease treated with infliximab.
Mizutani T; Akasaka R; Tomita K; Chiba T
Hepatogastroenterology; 2011; 58(110-111):1523-6. PubMed ID: 21940309
[TBL] [Abstract][Full Text] [Related]
13. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
15. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
[TBL] [Abstract][Full Text] [Related]
16. LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease.
Broekman MM; Roelofs HM; Hoentjen F; Wiegertjes R; Stoel N; Joosten LA; de Jong DJ; Wanten GJ
PLoS One; 2015; 10(7):e0133932. PubMed ID: 26208333
[TBL] [Abstract][Full Text] [Related]
17. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
[TBL] [Abstract][Full Text] [Related]
19. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with the loss of response to infliximab in patients with Crohn's disease.
Sono K; Yamada A; Yoshimatsu Y; Takada N; Suzuki Y
Cytokine; 2012 Aug; 59(2):410-6. PubMed ID: 22633084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
